Aldose reductase from Schistosoma japonicum: Crystallization and structure-based inhibitor screening for discovering antischistosomal lead compounds

Parasites and Vectors

Volumn 6, Issue 1, 2013, Pages

  Liu, Jian ^a,b   Dyer, David H ^c   Cheng, Jingdong ^d   Wang, Jipeng ^b   Wang, Shuqi ^b   Yang, Zhong ^b   Wang, Xiaoning ^b   Hu, Wei ^a,b  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d FUDAN UNIVERSITY   (China)

Author keywords

Aldose reductase (AR); Drug target; Schistosoma japonicum; Structure; Virtual screening

Indexed keywords

ALDEHYDE REDUCTASE; ALDEHYDE REDUCTASE INHIBITOR; ANTISCHISTOSOMAL AGENT; OXIDOREDUCTASE INHIBITOR; PRAZIQUANTEL; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ANTHELMINTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; FEMALE; HOST CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LC 50; MOBILIZATION; MORPHOLOGY; MORTALITY; MOUSE; NONHUMAN; SCHISTOSOMA JAPONICUM; X RAY DIFFRACTION;

ALDEHYDE REDUCTASE; ANIMALS; ANTHELMINTICS; BIOLOGICAL ASSAY; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HELMINTH PROTEINS; LOCOMOTION; PROTEIN CONFORMATION; SCHISTOSOMA JAPONICUM; SURVIVAL ANALYSIS;

SCHISTOSOMA; SCHISTOSOMA JAPONICUM;

EID: 84878432195     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/1756-3305-6-162     Document Type: Article

References (43)

1. Schistosomiasis control: experiences and lessons from China. Wang L, Utzinger J, Zhou XN, Lancet 2008 372 9652 1793 1795 10.1016/S0140-6736(08)61358- 6 18930529
2. Molecular characterization and ligand binding specificity of the PDZ domain-containing protein GIPC3 from Schistosoma japonicum. Mu Y, Huang H, Liu S, Cai P, Gao Y, Parasit Vectors 2012 5 227 10.1186/1756-3305-5-227 23050840
3. Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience. Chen MG, Acta Trop 2005 96 2-3 168 176 16125657
4. Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Alonso D, Munoz J, Gascon J, Valls ME, Corachan M, Am J Trop Med Hyg 2006 74 2 342 344 16474094 (Pubitemid 46774351)
5. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn NB, Mutuku MW, Karanja DM, Colley DG, Black CL, Secor WE, Mkoji GM, Loker ES, PLoS Negl Trop Dis 2009 3 8 504 10.1371/journal.pntd.0000504 19688043
6. Is there reduced susceptibility to praziquantel in Schistosoma japonicum? Evidence from China. Wang W, Dai JR, Li HJ, Shen XH, Liang YS, Parasitology 2010 137 13 1905 1912 10.1017/S0031182010001204 20810006
7. The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. Alger HM, Williams DL, Mol Biochem Parasitol 2002 121 1 129 139 10.1016/S0166-6851(02)00031-2 11985869 (Pubitemid 34457840)
8. Structural and functional characterization of Schistosoma mansoni Thioredoxin. Boumis G, Angelucci F, Bellelli A, Brunori M, Dimastrogiovanni D, Miele AE, Protein Sci 2011 20 6 1069 1076 10.1002/pro.634 21465612
9. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Arner ES, Williams DL, PLoS Med 2007 4 6 206 10.1371/journal.pmed.0040206 17579510 (Pubitemid 46998624)
10. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Rhee SG, Chae HZ, Kim K, Free Radic Biol Med 2005 38 12 1543 1552 10.1016/j.freeradbiomed.2005.02.026 15917183 (Pubitemid 40726061)
11. Redox balance mechanisms in Schistosoma mansoni rely on peroxiredoxins and albumin and implicate peroxiredoxins as novel drug targets. Sayed AA, Cook SK, Williams DL, J Biol Chem 2006 281 25 17001 17010 10.1074/jbc.M512601200 16606626
12. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Sayed AA, Simeonov A, Thomas CJ, Inglese J, Austin CP, Williams DL, Nat Med 2008 14 4 407 412 10.1038/nm1737 18345010 (Pubitemid 351499390)
13. Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells. Spycher SE, Tabataba-Vakili S, O'Donnell VB, Palomba L, Azzi A, FASEB J 1997 11 2 181 188 9039961 (Pubitemid 27097592)
14. Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Srivastava SK, Yadav UC, Reddy AB, Saxena A, Tammali R, Shoeb M, Ansari NH, Bhatnagar A, Petrash MJ, Srivastava S, Ramana KV, Chem Biol Interact 2011 191 1-3 330 338 21354119
15. Understanding the role of aldose reductase in ocular inflammation. Yadav UC, Srivastava SK, Ramana KV, Curr Mol Med 2010 10 6 540 549 20642441
16. Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase. Vander Jagt DL, Hunsaker LA, Chem Biol Interact 2003 143-144 341 351 22884955 (Pubitemid 36253593)
17. Pathogenesis of diabetic neuropathy-do hyperglycemia and aldose reductase inhibitors affect neuroactive steroid formation in the rat sciatic nerves? Colciago A, Negri-Cesi P, Celotti F, Exp Clin Endocrinol Diabetes 2002 110 1 22 26 10.1055/s-2002-19990 11835121 (Pubitemid 34136278)
18. Aldose reductase in keratinocytes attenuates cellular apoptosis and senescence induced by UV radiation. Kang ES, Iwata K, Ikami K, Ham SA, Kim HJ, Chang KC, Lee JH, Kim JH, Park SB, Yabe-Nishimura C, Seo HG, Free Radic Biol Med 2011 50 6 680 688 10.1016/j.freeradbiomed.2010.12.021 21182935
19. A glutathione-specific aldose reductase of Leishmania donovani and its potential implications for methylglyoxal detoxification pathway. Rath J, Gowri VS, Chauhan SC, Padmanabhan PK, Srinivasan N, Madhubala R, Gene 2009 429 1-2 1 9 18983902
20. Aldose reductase regulates vascular smooth muscle cell proliferation by modulating G1/S phase transition of cell cycle. Tammali R, Saxena A, Srivastava SK, Ramana KV, Endocrinology 2010 151 5 2140 2150 10.1210/en.2010-0160 20308528
21. Crystallization of ribozymes and small RNA motifs by a sparse matrix approach. Doudna JA, Grosshans C, Gooding A, Kundrot CE, Proc Natl Acad Sci U S A 1993 90 16 7829 7833 10.1073/pnas.90.16.7829 8356090 (Pubitemid 23250044)
22. Processing of X-ray diffraction data collected in oscillation mode. Otwinowski Z, Minor W, Macromol Crystall Pt A 1997 276 307 326 (Pubitemid 27085611)
23. Likelihood-enhanced fast translation functions. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ, Acta Crystallogr D: Biol Crystallogr 2005 61 Pt 4 458 464 (Pubitemid 43934606)
24. Coot: model-building tools for molecular graphics. Emsley P, Cowtan K, Acta Crystallogr D: Biol Crystallogr 2004 60 Pt 12 Pt 1 2126 2132 (Pubitemid 41742764)
25. PHENIX: building new software for automated crystallographic structure determination. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC, Acta Crystallogr D: Biol Crystallogr 2002 58 Pt 11 1948 1954 (Pubitemid 35337293)
26. The in vitro effect of mefloquine and praziquantel against juvenile and adult Schistosoma japonicum. Xiao SH, Mei JY, Jiao PY, Parasitol Res 2009 106 1 237 246 10.1007/s00436-009-1656-x 19851783
27. In vitro inhibition of lens aldose reductase by (2-benzyl-2,3,4,5- tetrahydro-1H-pyrido [4,3-b]indole-8-yl)-acetic acid in enzyme preparations isolated from diabetic rats. Djoubissie PO, Snirc V, Sotnikova R, Zurova J, Kyselova Z, Skalska S, Gajdosik A, Javorkova V, Vlkovicova J, Vrbjar N, Stefek M, Gen Physiol Biophys 2006 25 4 415 425 17356233 (Pubitemid 46420937)
28. Antischistosomal activity of trioxaquines: In vivo efficacy and mechanism of action on schistosoma mansoni. Portela J, Boissier J, Gourbal B, Pradines V, Colliere V, Cosledan F, Meunier B, Robert A, PLoS Negl Trop Dis 2012 6 2 1474 10.1371/journal.pntd.0001474 22348155
29. Structure of aldose reductase from Giardia lamblia. Ferrell M, Abendroth J, Zhang Y, Sankaran B, Edwards TE, Staker BL, Van Voorhis WC, Stewart LJ, Myler PJ, Acta Crystallogr Sect F Struct Biol Cryst Commun 2011 67 Pt 9 1113 1117 21904059
30. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Gallego O, Ruiz FX, Ardevol A, Dominguez M, Alvarez R, de Lera AR, Rovira C, Farres J, Fita I, Pares X, Proc Natl Acad Sci U S A 2007 104 52 20764 20769 10.1073/pnas.0705659105 18087047
31. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening. Zhao HT, Soda M, Endo S, Hara A, El-Kabbani O, Eur J Med Chem 2010 45 9 4354 4357 10.1016/j.ejmech.2010.05.032 20538382
32. Low-molecular-mass antioxidants in parasites. Krauth-Siegel RL, Leroux AE, Antioxid Redox Signal 2012 17 4 583 607 10.1089/ars.2011.4392 22053812
33. Hysteresis in thioredoxin-glutathione reductase (TGR) from the adult stage of the liver fluke Fasciola hepatica. Guevara-Flores A, Pardo JP, Rendon JL, Parasitol Int 2011 60 2 156 160 10.1016/j.parint.2011.01.005 21295157
34. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(varepsilon)-carboxymethyl lysine. Kawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M, Hirata T, Saruta T, Shimada A, Itoh H, J Diabetes Complications 2010 24 6 424 432 10.1016/j.jdiacomp.2008.10.005 19716319
35. The anti-schistosomal drug praziquantel is an adenosine antagonist. Angelucci F, Basso A, Bellelli A, Brunori M, Pica Mattoccia L, Valle C, Parasitology 2007 134 Pt 9 1215 1221 17428352 (Pubitemid 47174071)
36. Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma. Jamal-Hanjani M, Pettengell R, Expert Opin Drug Metab Toxicol 2011 7 11 1441 1448 10.1517/17425255.2011.618834 21905966
37. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, Pharmacol Rev 2004 56 2 185 229 10.1124/pr.56.2.6 15169927 (Pubitemid 38720829)
38. Mitoxantrone as a prospective photosensitizer for photodynamic therapy of breast cancer. Montazerabadi AR, Sazgarnia A, Bahreyni-Toosi MH, Ahmadi A, Shakeri-Zadeh A, Aledavood A, Photodiagnosis Photodyn Ther 2012 9 1 46 51 10.1016/j.pdpdt.2011.08.004 22369728
39. Potentiation of the antimalarial agent rufigallol. Winter RW, Cornell KA, Johnson LL, Ignatushchenko M, Hinrichs DJ, Riscoe MK, Antimicrob Agents Chemother 1996 40 6 1408 1411 8726010 (Pubitemid 26169997)
40. Analysis of rhubarb anthraquinones and bianthrones by microemulsion electrokinetic chromatography. Sun SW, Yeh PC, J Pharm Biomed Anal 2005 36 5 995 1001 10.1016/j.jpba.2004.08.039 15620525 (Pubitemid 40037819)
41. Microcalorimetric assay on the antimicrobial property of five hydroxyanthraquinone derivatives in rhubarb (Rheum palmatum L.) to Bifidobacterium adolescentis. Wang J, Zhao H, Kong W, Jin C, Zhao Y, Qu Y, Xiao X, Phytomedicine 2010 17 8-9 684 689 19962872
42. Discovery of new inhibitors of Schistosoma mansoni PNP by pharmacophore-based virtual screening. Postigo MP, Guido RV, Oliva G, Castilho MS, da RPI, de Albuquerque JF, Andricopulo AD, J Chem Inf Model 2010 50 9 1693 1705 10.1021/ci100128k 20695479
43. Development of an in vitro drug screening assay using Schistosoma haematobium schistosomula. Marxer M, Ingram K, Keiser J, Parasit Vectors 2012 5 165 10.1186/1756-3305-5-165 22876861